Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vancomycin | 5 | 2024 | 75 | 1.510 |
Why?
|
| Anti-Bacterial Agents | 12 | 2023 | 1471 | 1.450 |
Why?
|
| Teicoplanin | 2 | 2021 | 17 | 0.940 |
Why?
|
| Ritonavir | 2 | 2023 | 71 | 0.860 |
Why?
|
| beta-Lactamases | 1 | 2022 | 25 | 0.780 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 10 | 0.750 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 192 | 0.740 |
Why?
|
| Aspergillosis | 1 | 2021 | 23 | 0.740 |
Why?
|
| Candidiasis | 1 | 2021 | 51 | 0.740 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 637 | 0.680 |
Why?
|
| Organ Transplantation | 1 | 2022 | 159 | 0.660 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 340 | 0.660 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2023 | 300 | 0.660 |
Why?
|
| Blood Coagulation Factors | 1 | 2018 | 43 | 0.600 |
Why?
|
| Outpatients | 4 | 2023 | 325 | 0.510 |
Why?
|
| Sepsis | 1 | 2020 | 507 | 0.470 |
Why?
|
| Hemorrhage | 1 | 2018 | 600 | 0.460 |
Why?
|
| Critical Illness | 1 | 2019 | 640 | 0.440 |
Why?
|
| Kidney | 2 | 2023 | 1182 | 0.440 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 674 | 0.400 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 239 | 0.360 |
Why?
|
| Retrospective Studies | 11 | 2024 | 12521 | 0.260 |
Why?
|
| Humans | 23 | 2024 | 114043 | 0.260 |
Why?
|
| Tetracyclines | 1 | 2023 | 5 | 0.230 |
Why?
|
| beta-Lactams | 2 | 2023 | 27 | 0.220 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 37 | 0.220 |
Why?
|
| Endocarditis | 1 | 2024 | 32 | 0.220 |
Why?
|
| Immune Reconstitution | 1 | 2023 | 6 | 0.220 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 949 | 0.210 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 10 | 0.210 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 15 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 91 | 0.200 |
Why?
|
| Mycobacterium abscessus | 1 | 2023 | 95 | 0.190 |
Why?
|
| Creatinine | 2 | 2023 | 424 | 0.190 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 41 | 0.190 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 137 | 0.190 |
Why?
|
| Clostridium Infections | 1 | 2022 | 54 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 180 | 0.190 |
Why?
|
| Daptomycin | 1 | 2021 | 18 | 0.180 |
Why?
|
| Cephalosporins | 1 | 2021 | 26 | 0.180 |
Why?
|
| Plasmids | 1 | 2022 | 343 | 0.180 |
Why?
|
| Antifungal Agents | 1 | 2021 | 128 | 0.170 |
Why?
|
| Burns | 1 | 2023 | 237 | 0.170 |
Why?
|
| Salvage Therapy | 1 | 2021 | 127 | 0.170 |
Why?
|
| Adult | 7 | 2024 | 30375 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 520 | 0.170 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 61 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2023 | 328 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 486 | 0.150 |
Why?
|
| Vitamin K | 1 | 2018 | 42 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 519 | 0.150 |
Why?
|
| Hemostatics | 1 | 2018 | 44 | 0.150 |
Why?
|
| Isoantibodies | 1 | 2017 | 52 | 0.140 |
Why?
|
| Bacterial Proteins | 1 | 2022 | 735 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2017 | 220 | 0.130 |
Why?
|
| Graft Survival | 1 | 2017 | 443 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 614 | 0.120 |
Why?
|
| Logistic Models | 1 | 2019 | 1829 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2017 | 511 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 955 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2023 | 61 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2537 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2017 | 670 | 0.100 |
Why?
|
| Standard of Care | 2 | 2022 | 62 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 18969 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2343 | 0.090 |
Why?
|
| Risk Factors | 2 | 2019 | 8614 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2023 | 642 | 0.070 |
Why?
|
| Male | 6 | 2024 | 55396 | 0.070 |
Why?
|
| Middle Aged | 3 | 2024 | 26605 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1257 | 0.060 |
Why?
|
| Female | 5 | 2024 | 59325 | 0.060 |
Why?
|
| Hospitalization | 2 | 2022 | 1762 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2023 | 66 | 0.050 |
Why?
|
| Piperacillin | 1 | 2023 | 8 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 16 | 0.050 |
Why?
|
| Minocycline | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 143 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2023 | 136 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2022 | 330 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2023 | 200 | 0.050 |
Why?
|
| Gentamicins | 1 | 2021 | 42 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 222 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 68 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 605 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 315 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 158 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 925 | 0.040 |
Why?
|
| Bacteremia | 1 | 2021 | 160 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 813 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 1075 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1422 | 0.030 |
Why?
|
| Colorado | 1 | 2023 | 4090 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 1125 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 2505 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1764 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 3397 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 9049 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 5038 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 7943 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 9114 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 17800 | 0.010 |
Why?
|
| Child | 1 | 2017 | 18400 | 0.010 |
Why?
|